Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS OIG promotes self disclosure protocol

This article was originally published in The Gray Sheet

Executive Summary

HHS Inspector General Daniel Levinson announces a new initiative for healthcare providers to resolve conduct that may otherwise result in civil monetary penalties for physician self-referral and anti-kickback violations. In an April 24 "open letter," Levinson says the proposal is intended to provide guidance to supplement the self-disclosure protocol, which the IG says can lead to issuance of certification of compliance agreements to settle healthcare fraud as an alternative to more extensive corporate integrity agreements. The OIG's 1998 self-disclosure protocol is a mechanism for healthcare providers to investigate, quantify and resolve potential fraud. The new self-disclosure initiative offers providers the ability to work collaboratively with OIG, the letter states...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel